Skip to main content
Advertisement
Advertisement
BIO
BIO logo
Bio-Rad Laboratories, Inc.Class A
369.95
USD
Sponsored
+6.45
+1.77%
Oct 23, 15:59 UTC -4
Closed
exchange

After-Market

369.94

-0.01
0.00%

Bio-Rad Laboratories, Inc.Class A (BIO) Earnings

BIO Earnings Reports

Positive Surprise Ratio

BIO beat 30 of 43 last estimates.

70%

Next Report

Date of Next Report
Nov 04, 2026
Estimate for Q3 26 (Revenue/ EPS)
$656.45M
/
$2.24
Implied change from Q2 26 (Revenue/ EPS)
+0.84%
/
-14.50%
Implied change from Q3 25 (Revenue/ EPS)
+0.53%
/
-0.44%

Bio-Rad Laboratories, Inc.Class A earnings per share and revenue

On Aug 04, 2026, BIO reported earnings of 2.62 USD per share (EPS) for Q2 26, beating the estimate of 1.76 USD, resulting in a 48.43% surprise. Revenue reached 651.00 million, compared to an expected 630.23 million, with a 3.30% difference. The market reacted with a +4.50% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 6 analysts forecast an EPS of 2.24 USD, with revenue projected to reach 656.45 million USD, implying an decrease of -14.50% EPS, and increase of 0.84% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Abbott Laboratories
Report Date
Oct 21, 2026 For Q3 26
Estimate
$1.42
Actual
$1.42
Surprise
-0.68%
FAQ
For Q2 2026, Bio-Rad Laboratories, Inc.Class A reported EPS of $2.62, beating estimates by 48.43%, and revenue of $651.00M, 3.3% above expectations.
The stock price moved up 4.5%, changed from $332.88 before the earnings release to $347.86 the day after.
The next earning report is scheduled for Nov 04, 2026.
Based on 6 analysts, Bio-Rad Laboratories, Inc.Class A is expected to report EPS of $2.24 and revenue of $656.45M for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement